The essential aim of WP4, led by the University of Liverpool, is to determine whether novel media applications (apps and social media) add value to existing pharmacovigilance methodologies. There is close interaction with WP1, as the outputs of these activities will directly impact policy recommendations into the utility of the tools, and the position they occupy alongside traditional pharmacovigilance activities.

This work package will develop an understanding of where social media sits within the hierarchy of evidence, and on its use in signal detection and evaluation activities, gaining an understanding of the likely impact of treating social media like traditional ADR reports. Also, WP4 will focus on evaluation of the data generated via the mobile app. Reports received via the mobile app will be compared to those received via established reporting schemes for completeness, quality and value for detection of safety issues. Activities undertaken will include benchmarking reports from the app against those from traditional sources with respect to quantity, quality and appropriateness. Further activities will be undertaken to evaluate the impact of such reports on signal detection and as with social media the impacts of integration with traditional sources.

Partners involved

  • University of Liverpool
  • Uppsala Monitoring Centre
  • University College London
  • Novartis Pharma
  • Janssen Pharmaceutica
  • Bayer
  • AstraZeneca
  • Sanofi-Aventis Research & Development
  • UCB
  • Amgen